• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

March 8, 2013
CenterWatch Staff

King’s College London, The Wellcome Trust and Advent Venture Partners have announced the formation of a new U.K. biotechnology company, CoCo Therapeutics, to progress the research of Professor Jonathan Corcoran into the development of new treatments for Alzheimer’s disease.

The company will build on the success of research funded through the Wellcome Trust’s Seeding Drug Discovery initiative investigating the role of the retinoic acid receptor, RAR-alpha, and molecules that act on it in Alzheimer’s disease.

The neuroscience drug discovery unit at King’s, led by Professor Corcoran, has been optimizing compounds for treatment of CNS disorders since 2008. The group previously has shown that molecules that act on RAR-alpha can affect multiple parts of the Alzheimer’s pathway and have the potential to produce an effective therapy that would otherwise need several points of intervention from different drugs. CoCo Therapeutics now will take forward the lead compound into late-stage preclinical studies and clinical trials.

Funding has been provided by Advent Venture Partners, one of Europe's venture capital investors in technology and life sciences businesses. Dr. Raj Parekh, general partner at Advent, will be the founding chairman of the new company.

 “Our research has shown early promise in this area and this partnership will enable us to progress the work further,” said Corcoran. “This is an exciting step forward in the search for effective Alzheimer's disease treatments.”

CoCo Therapeutics also has named Dr. Steve Butcher chief operating officer. Dr. Butcher was a founder and scientific director of the Fujisawa Institute of Neuroscience before holding management positions at Pharmacia. More recently, he held executive positions in biotechnology companies including BioImage and TopoTarget.

Enter Content Here

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing